Slide 1: Q3 FY26 Earnings
Q3 FY26 Earnings April 30, 2026
Slide 2: Presentation of financial information & forward-looking statements
Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepar
Slide 3: Resmed | The global leader in connected and digital health
Resmed | The global leader in connected and digital health Key Statistics Headquarters San Diego, CA 12% 12% Founded 1989 Revenue Revenue Listed (NYSE, ASX) 1995, RMD by business by region 37% 30% LTM 3Q26 51% LTM 3Q26 58% LTM 3Q26 revenue $5.5B LTM 3Q26 operating margin 34% | 36% (GAAP/Non-GAAP) Co
Slide 4: More than 26 billion nights of respiratory medical data (up ~1B)
Resmed | The global leader in connected and digital health More than 26 billion nights of respiratory medical data (up ~1B) 36+ million Up ~1M 34+ million Up ~1M patients in AirView 100% cloud connectable devices worldwide v 4.6+ million Up ~0.1M v 178+ million Up ~4M diagnostic tests processed in t
Slide 5: We are creating a more efficient, effective pathway to care
We are creating a more efficient, effective pathway to care OPT -IN MAKE THERAPY CHOICE ON THERAPY LIFETIME VALUE STAGE STAGE STAGE STAGE STAGE STAGE STAGE 1 2 3 4 5 6 7 Awareness Testing Diagnosis Prescribed PAP Start PAP therapy Compliant in 90 Days Remain after 1 Year Somnoware myAir Brightree RE
Slide 6: Resmed is an innovation machine across hardware, software, and digital patient interfaces
Resmed is an innovation machine across hardware, software, and digital patient interfaces AirSenseTM 11 Rollout to Global Markets AirTouchTM N30i AirTouchTM F30i • Award-winning fabric-wrapped nasal • Award-winning fabric-based full-face mask • Most recently launched in China and mask designed to de
Slide 7: Clinicians are highly engaged with Resmed education programs
Clinicians are highly engaged with Resmed education programs focused on sleep ✓More than 80,000 CME courses completed Up ~20K ✓By >45,000 clinicians Up ~10K ✓With ~78% clinical practices with regards to OSA Saying they intend to change their Up from ~77% Note: Data as of March 31, 2026. © 2026 Resme
Slide 8: Real-world data analysis in sleep apnea population shows significant positive correlation between GLP-1s and PAP therapy
Real-world data analysis in sleep apnea population shows significant positive correlation between GLP-1s and PAP therapy GLP-1 initiated1,2 vs. non-GLP-1 initiated OSA patients1 Patients with an OSA diagnosis Likely to initiate PAP resupply rates4 PAP resupply rates4 and prescribed a PAP therapy3 1-
Slide 9: Expanding our broader sleep health portfolio with Noctrix, an FDA De Novo classified device
Expanding our broader sleep health portfolio with Noctrix, an FDA De Novo classified device indicated for refractory moderate-to-severe Restless Leg Syndrome (RLS) RLS Attractiveness Nidra Therapy Traction • RLS affects ~7% of adults globally1 • Nidra highly resonating with patients and prescribers4
Slide 10: 5-year global outlook underpinned by strong foundation and execution of 2030 strategy
5-year global outlook underpinned by strong foundation and execution of 2030 strategy 5-Year Global Outlook Underpinned by 2030 Strategy: High single digits + Increasing overall market growth via accelerating demand generation % Revenue Growth + Optimizing the patient pathway to diagnosis and therap
Slide 11: Q3 Financial Results
Q3 Financial Results
Slide 12: Q3 FY26 financial results
Q3 FY26 financial results YoY Revenue Trajectory Revenue by Segment Revenue by and Region Business ($ in millions) Revenue % by Segment $1,431.4 12% Devices Masks and other $1,291.7 51% 37% RCS Revenue % by Region U.S., Canada, & 12% Latin America Europe, Asia, & 31% Other 57% RCS (U.S. & Q3 FY25 Q3
Slide 13: Q3 FY26 financial results (cont'd)
Q3 FY26 financial results (cont’d) Gross Margin Operating Income Earnings per Share ($ in millions) ($ in actuals) GAAP 62.2% $499.8 59.3% $2.74 $426.3 $2.48 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Non-GAAP $524.8 $2.86 62.8% $444.6 59.9% $2.37 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26
Slide 14: FY26 global outlook underpinned by strong financial management
FY26 global outlook underpinned by strong financial management Gross Margin, Non-GAAP1 62%- 63% 62.8% 62.3% 62.0% 61.4% 4Q25 1Q26 2Q26 3Q26 FY26 Pipeline of Margin Improvement Drivers + Platform standardization + Component cost improvements + Logistics efficiencies / Freight optimization + Scale Ben
Slide 15: Strong free cash flow and balance sheet
Strong free cash flow and balance sheet Operating Cash Flow Capital Expenditures Free Cash Flow As of March 31, 2026: ($ in millions) ($ in millions) ($ in millions) $1,890.0 Total debt outstanding ~$664M $1,652.9 $1,754.2 $1,568.8 Less: Cash & cash equiv. ~$1,661M $1,198.6 $1,089.6 $135.7 Net Cash
Slide 16: Track record of strong financial returns for shareholders
Track record of strong financial returns for shareholders Revenue Operating Income Earnings per Share ($ in millions) ($ in millions) ($ in actuals) $5,538 GAAP $1,893 GAAP $10.37 +12% CAGR +16% CAGR +27% CAGR $3,091 $885 $3.13 LTM 3Q21 LTM 3Q26 LTM 3Q21 LTM 3Q26 LTM 3Q21 LTM 3Q26 Free Cash Flow1 No
Slide 17: Disciplined capital allocation supports both business growth and return of capital to shareholders
Disciplined capital allocation supports both business growth and return of capital to shareholders Strategic • 6-7% of revenue invested in R&D2 Capital deployed over last 3 years Growth Reinvest Priorities for Growth • Q3 FY26 capital expenditures of ~$34M (through March 31, 2026) • Tuck-in size acq
Slide 18: Select outlook items
Select outlook items (FY26 Outlook as of April 30, 2026) Metric 1 Non-GAAP Gross Margin % 62% – 63% SG&A % of Revenue 19% – 20% R&D % of Revenue 6% – 7% 1 Non-GAAP Tax Rate % 21% – 23% (Q4 FY26 Outlook as of April 30, 2026) Metric Net Interest Income ~$15M Share Repurchases Planned ≥$175M 1 Non-GAAP
Slide 19: Resmed | A compelling investment opportunity
Resmed | A compelling investment opportunity ✓ Target markets are very large and significantly underpenetrated ✓ Key mega trends in big tech and pharma are driving patients to our sleep ecosystem ✓ Resmed is well-positioned with differentiated products, a robust innovation pipeline, and supply chain
Slide 20: Contact Investor Relations
Contact Investor Relations Phone: +1 (858) 221-3304 Email: InvestorRelations@Resmed.com Website: Investor.Resmed.com
Slide 21: Appendix
APPENDIX
Slide 22: Large, underpenetrated total addressable market = long runway for growth
Large, underpenetrated total addressable market = long runway for growth MARKET FOR DEVICES MARKET FOR MASKS Growing in the Growing in the mid-single digits high-single digits globally globally 480M COPD Underpenetrated OSA Market1 Overlap syndrome <20% <10% U.S. Rest of World 850M COMISA 1B People
Slide 23: Key megatrends are driving patients and providers to Resmed's ecosystem
Key megatrends are driving patients and providers to Resmed’s ecosystem Consumers are Widespread Wearables Consumers AI and digital Massive pressure more focused adoption of spotlight sleep demand an health are on healthcare on their health GLP-1 apnea and elevated changing how systems; payers / th
Slide 24: Strategy 2030
2030 OUR STRATEGY OUR OUR KEY Strategy FOCUS AREAS CAPABILITIES We will create products people love as well as Sleep Health seamless, personalized Empower our teams pathways for access to Breathing Health life-changing care Prioritize AI OUR OUR Health Tech at Home Build trust FINANCIAL MISSION GOAL
Slide 25: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are reconciled below: (Unaudited; $ in thousands, except for per share amounts) Note regarding non-GAAP reconciliations (A) Resmed
Slide 26: Reconciliation of non-GAAP financial measures (cont'd)
Reconciliation of non-GAAP financial measures (cont’d) The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below: (U
Slide 27: Reconciliation of non-GAAP financial measures (cont'd)
Reconciliation of non-GAAP financial measures (cont’d) The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below: (Unaudited; $ in thousands, except for per share amounts) Note regarding non-GAAP reconciliations (A) Resmed adjusts for the impact of the amorti
Slide 28: Reconciliation of non-GAAP financial measures (cont'd)
Reconciliation of non-GAAP financial measures (cont’d) The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: (Unaudited; $ in thousands, except for per share amounts) Note regarding non